The usage of chatbots on Pharmaceutical websites 2026
Tuesday 12th May 2026
Healthcare professionals and other stakeholders increasingly expect quick and convenient online communication channels. Despite this, adoption of website chatbot functionality within pharmaceutical companies remains limited.
Chatbox adoption across leading Pharmaceutical companies
Tela has analysed 44 leading pharmaceutical companies in the UK to determine their use of website chatbox functionality. The findings reveal that only 2 companies (approximately 5%) currently utilise chatbots on their websites while 42 companies (95%) do not.
The companies identified as using chat functionality are:
The remaining 42 companies, including prominent names such as AstraZeneca, Novartis, Roche, Sanofi and Johnson & Johnson, do not currently offer chatbot functionality on their websites.
Potential factors behind low chatbot adoption
Several factors may explain why chatbots have seen limited implementation across the pharmaceutical sector:
Regulatory and compliance constraints
Pharmaceutical companies operate in a highly regulated environment. Implementing live chat or AI-driven tools requires careful management of patient confidentiality, data protection and regulatory compliance. Even minor errors in responses could carry legal or reputational risks.
Brand positioning
Many pharmaceutical companies emphasise formal, controlled channels for communication, often prioritising direct contact via email, call centres or approved portals for healthcare professionals. Chatbots may be perceived as inconsistent with this approach.
Operational and resource considerations
Maintaining an effective chat solution requires trained staff, AI oversight or sophisticated natural language processing systems to ensure responses are accurate, reliable and aligned with medical guidelines.
Final thoughts
Although current adoption levels are low, the expectations of stakeholders are evolving. Healthcare professionals and patients increasingly value immediate and convenient online interactions. As competition intensifies and digital transformation accelerates, pharmaceutical companies may face increasing pressure to adopt tools that enhance accessibility and responsiveness on their websites.
For the two companies that have implemented chat functionality, early adoption may offer a competitive advantage, improving engagement and positioning themselves as digitally forward-thinking within the sector.